BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18388340)

  • 1. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
    Shinohara Y; Nishimaru K; Sawada T; Terashi A; Handa S; Hirai S; Hayashi K; Tohgi H; Fukuuchi Y; Uchiyama S; Yamaguchi T; Kobayashi S; Kondo K; Otomo E; Gotoh F;
    Stroke; 2008 Jun; 39(6):1827-33. PubMed ID: 18388340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
    Shinohara Y; Nishimaru K;
    Stroke; 2009 Aug; 40(8):2862-5. PubMed ID: 19520981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
    Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
    Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
    Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
    Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
    Huang Y; Cheng Y; Wu J; Li Y; Xu E; Hong Z; Li Z; Zhang W; Ding M; Gao X; Fan D; Zeng J; Wong K; Lu C; Xiao J; Yao C;
    Lancet Neurol; 2008 Jun; 7(6):494-9. PubMed ID: 18456558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
    Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
    Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan.
    Takahashi S; Mizuno O; Sakaguchi T; Yamada T; Inuyama L
    Adv Ther; 2014 Jan; 31(1):118-29. PubMed ID: 24385407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.
    Shinohara Y; Katayama Y; Uchiyama S; Yamaguchi T; Handa S; Matsuoka K; Ohashi Y; Tanahashi N; Yamamoto H; Genka C; Kitagawa Y; Kusuoka H; Nishimaru K; Tsushima M; Koretsune Y; Sawada T; Hamada C;
    Lancet Neurol; 2010 Oct; 9(10):959-68. PubMed ID: 20833591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.
    Culebras A; Rotta-Escalante R; Vila J; Domínguez R; Abiusi G; Famulari A; Rey R; Bauso-Tosselli L; Gori H; Ferrari J; Reich E;
    Neurology; 2004 Apr; 62(7):1073-80. PubMed ID: 15079004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
    Hong KS; Kim BJ; Lee JY; Kwon SU;
    Int J Stroke; 2015 Oct; 10(7):1153-8. PubMed ID: 26044566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial.
    Ueda H; Kido A; Matsuhisa S; Asawa K; Yoshida N; Tsujimoto M; Sasaki Y; Kuga Y; Yamasaki M; Ueda K; Shinohara S; Nishida Y
    Am Heart J; 2016 Mar; 173():134-42. PubMed ID: 26920606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
    Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
    Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
    Alvarez-Sabín J; Quintana M; Santamarina E; Maisterra O
    Cerebrovasc Dis; 2014; 37(3):181-7. PubMed ID: 24503927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose aspirin for preventing recurrent venous thromboembolism.
    Brighton TA; Eikelboom JW; Mann K; Mister R; Gallus A; Ockelford P; Gibbs H; Hague W; Xavier D; Diaz R; Kirby A; Simes J;
    N Engl J Med; 2012 Nov; 367(21):1979-87. PubMed ID: 23121403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial.
    Deja MA; Kargul T; Domaradzki W; Stącel T; Mazur W; Wojakowski W; Gocoł R; Gaszewska-Żurek E; Żurek P; Pytel A; Woś S
    J Thorac Cardiovasc Surg; 2012 Jul; 144(1):204-9. PubMed ID: 22554721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessment of defibrase in treatment of acute cerebral infarction: a multicenter, randomized, double-blind, placebo-controlled trial.
    Cooperative Group for Reassessment of Defibrase
    Chin Med Sci J; 2005 Sep; 20(3):151-8. PubMed ID: 16261883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.